Blisibimod

N/A

Report date: 2022/11/25 18:07:52

Base Information

Drug NameBlisibimod
Drug Alias NameBlisibimodum布利莫德A-623AMG-623
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicGlomerulonephritis, IGA +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSingapore +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAnthera
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAnthera Pharmaceuticals IncAmgen Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicPurpura, Thrombocytopenic, IdiopathicGlomerulonephritis, IGA +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG